美国 Wistar研究所研制的新型原型流感疫苗可以无需每年注射。由 Gerhard等研制的甲型流感疫苗与现行的疫苗相比 ,针对的是较稳定的流感病毒区域 ,并且它是鼻用制剂 ,无需注射。　　现行流感疫苗相当有效 ,但它们针对的是一对迅速变异的病毒外膜蛋白 ,因此 ,生产厂家面临的问题 The new prototype influenza vaccine developed by the Wistar Institute in the United States eliminates the need for annual injections. The Influenza A vaccine developed by Gerhard et al. Is more stable against influenza virus than the current vaccine and it is a nasal formulation without injection. The current flu vaccines are quite effective, but they target a pair of rapidly mutating viral outer membrane proteins, so the problems manufacturers face